All In Biotech

Drug Trial Radar · NCT06178991

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.

A PHASE 3, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID-19 AND INFLUENZA IN HEALTHY INDIVIDUALS

Last checked: Nov 20, 2026Latest source record: Dec 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 8,795 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

8,795

Actual

Start

Dec 20, 2023

Primary completion

Nov 26, 2024

Study completion Nov 26, 2024

Sponsor

Lead sponsor
BioNTech SEIndustry
Sponsor type
Industry
Collaborators
Pfizer
First posted
Dec 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to understand the safety and effects of a combined influenza and COVID-19 vaccine. This combined vaccine is compared to separate vaccines for the protection against influenza and SARS-CoV-2. Influenza and COVID-19 are diseases that can spread easily from one person to another and cause body aches, fever, cough, and other symptoms. Giving both influenza and COVID-19 vaccines together against influenza and SARS-CoV-2 could provide great benefits to both patients and caregivers in terms of simple and easy care. Around 8550 participants will be assigned into 1 of 8 vaccination groups (Group A, B, C, D, E, F, G or H) by chance. Cohort 1: Approximately 450 participants will be assigned by chance to one of the following: * Group A:Influenza and COVID-19 combination A vaccine, given at the same time in one arm and placebo (an injection consisting of just salt water and no medicines in it) in the opposite arm. * Group B: COVID-19 vaccine, given at the same time to one arm and licensed influenza vaccine in the opposite arm. Cohort 2: Approximately 4500 participants will be assigned by chance to one of the following: * Group C: Influenza and COVID-19 combination B vaccine, given at the same time in one arm and placebo in the opposite arm. * Group D: COVID-19 vaccine, given at the same time in one arm and licenced influenza vaccine in the opposite arm. Cohort 3: Approximately 3600 participants will be assigned by chance to one of the following: * Group E: Influenza and COVID-19 combination B vaccine. * Group F: COVID-19 vaccine. * Group G: Licenced influenza vaccine. * Group H: Investigational influenza vaccine. All participants in cohort 1 and cohort 2 will receive 2 injections and participants in cohort 3 will receive 1 injection as per their assigned study group at Visit 1. The participants will be followed for about 6 months. During this time, researchers will assess safety and the body's reaction to the vaccination over approximately 6 months. This will help understand if the study medicine is safe.

Conditions

  • Influenza
  • COVID-19

Interventions

  • Influenza and COVID-19 Combination ABiological

    Combined influenza and Pfizer-BioNTech COVID-19 Vaccine

  • Licensed influenza vaccineBiological

    Licensed influenza vaccine

  • COVID-19 VaccineBiological

    Pfizer-BioNTech COVID-19 vaccine

  • Influenza and COVID-19 Combination BBiological

    Combined influenza and Pfizer-BioNTech COVID-19 vaccine

  • PlaceboBiological

    Saline Solution

  • Investigational influenza vaccineBiological

    Investigational influenza vaccine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1: Percentage of Participants With Any Local Reactions for up to 7 Days Following Vaccination in Investigational Vaccine ExtremityTime frame: From Day 1 through Day 7 after Vaccination [Vaccination on Day 1]
  2. Cohort 2: Percentage of Participants With Any Local Reactions for up to 7 Days Following Vaccination in Investigational Vaccine ExtremityTime frame: From Day 1 through Day 7 after Vaccination [Vaccination on Day1]
  3. Cohort 3: Percentage of Participants With Any Local Reactions for up to 7 Days Following Vaccination in Investigational Vaccine ExtremityTime frame: From Day 1 through Day 7 after Vaccination [Vaccination on Day 1]
  4. Cohort 1: Percentage of Participants With Any Systemic Events for up to 7 Days Following VaccinationTime frame: From Day 1 through Day 7 after Vaccination [Vaccination on Day 1]
  5. Cohort 2: Percentage of Participants With Any Systemic Events for up to 7 Days Following VaccinationTime frame: From Day 1 through Day 7 after Vaccination [Vaccination on Day 1]
  6. Cohort 3: Percentage of Participants With Any Systemic Events for up to 7 Days Following VaccinationTime frame: From Day 1 through Day 7 after Vaccination [Vaccination on Day 1]
  7. Cohort 1: Percentage of Participants Reporting Adverse Events (AEs) From Vaccination Through 4 Weeks After VaccinationTime frame: From Vaccination on Day 1 through 4 Weeks after Vaccination
  8. Cohort 2: Percentage of Participants Reporting AEs From Vaccination Through 4 Weeks After VaccinationTime frame: From Vaccination on Day 1 through 4 Weeks after Vaccination
  9. Cohort 3: Percentage of Participants Reporting AEs From Vaccination Through 4 Weeks After VaccinationTime frame: From Vaccination on Day 1 through 4 Weeks after Vaccination
  10. Cohort 1: Percentage of Participants Reporting SAEs From Vaccination Through 6 Months After VaccinationTime frame: From Vaccination on Day 1 through 6 Months after Vaccination
  11. Cohort 2: Percentage of Participants Reporting SAEs From Vaccination Through 6 Months After VaccinationTime frame: From Vaccination on Day 1 through 6 Months after Vaccination
  12. Cohort 3: Percentage of Participants Reporting SAEs From Vaccination Through 6 Months After VaccinationTime frame: From Vaccination on Day 1 through 6 Months after Vaccination
  13. Cohort 2: Geometric Mean Titer (GMT) and Geometric Mean Ratio (GMR) of Strain-Specific Hemagglutination Inhibition Assay (HAI) Titers at 4 Weeks After Vaccination: Non-inferiorityTime frame: At 4 Weeks after Vaccination
  14. Cohort 2: Percentage of Participants and Difference in Percentage of Participants With Strain-Specific HAI Seroconversion at 4 Weeks After Vaccination: Non-inferiorityTime frame: At 4 Weeks after Vaccination
  15. Cohort 2: GMT and GMR of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Neutralizing Titers at 4 Weeks After Vaccination: Non-inferiorityTime frame: At 4 Weeks after Vaccination
  16. Cohort 2: Percentage of Participants and Difference in Percentage of Participants With SARS-CoV-2 Seroresponse at 4 Weeks After Vaccination: Non-inferiorityTime frame: At 4 Weeks after Vaccination

Locations

106 sites in 1 country. Site status is shown where the registry gives one.

  • North Alabama Research Center

    Athens, Alabama

  • Accel Research Sites - Birmingham Clinical Research Unit

    Birmingham, Alabama

  • AMR Clinical

    Mobile, Alabama

  • HOPE Research Institute

    Phoenix, Arizona

  • Foothills Research Center/ CCT Research

    Phoenix, Arizona

  • Scottsdale Clinical Trials

    Scottsdale, Arizona

  • Alliance for Multispecialty Research, LLC

    Tempe, Arizona

  • Baptist Health Center For Clinical Research

    Little Rock, Arkansas

  • Hope Clinical Research, Inc.

    Canoga Park, California

  • Ascada Health PC dba Ascada Research

    Fullerton, California

  • Orange County Research Center

    Lake Forest, California

  • Ark Clinical Research

    Long Beach, California

  • Collaborative Neuroscience Research, LLC

    Los Alamitos, California

  • Artemis Institute for Clinical Research

    San Diego, California

  • Acclaim Clinical Research

    San Diego, California

  • Bayview Research Group, LLC

    Valley Village, California

  • Synexus Clinical Research US, Inc.

    Vista, California

  • Diablo Clinical Research, Inc.

    Walnut Creek, California

  • Tampa Bay Medical Research

    Clearwater, Florida

  • Universal Axon Clinical Research, LLC

    Doral, Florida

  • Proactive Clinical Research,LLC

    Fort Lauderdale, Florida

  • Finlay Medical Research

    Greenacres City, Florida

  • Indago Research & Health Center, Inc

    Hialeah, Florida

  • Best Quality Research,Inc.

    Hialeah, Florida

  • Clinical Neuroscience Solutions, Inc. dba CNS Healthcare

    Jacksonville, Florida

  • Miami Clinical Research

    Miami, Florida

  • Gerardo Polanco, MD

    Miami, Florida

  • Research Institute of South Florida

    Miami, Florida

  • Entrust Clinical Research

    Miami, Florida

  • Miami Dade Medical Research Institute, LLC

    Miami, Florida

  • Clinical Site Partners LLC, dba Flourish Research

    Miami, Florida

  • Palm Springs Community Health Center

    Miami Lakes, Florida

  • Angels Clinical Research Institute

    Miami Lakes, Florida

  • Clinical Neuroscience Solutions, Inc.

    Orlando, Florida

  • Innovation Medical Research Center

    Palmetto Bay, Florida

  • DBC Research USA

    Pembroke Pines, Florida

  • Angels Clinical Research Institute

    Tampa, Florida

  • Centricity Research Columbus Georgia Multispecialty

    Columbus, Georgia

  • AGILE Clinical Research Trials, LLC

    Sandy Springs, Georgia

  • Clinical Research Atlanta

    Stockbridge, Georgia

Showing 40 of 106 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.